Adenocarcinoma of esophago-gastric junction
Conditions
Interventions
Protocol of Naqbpacritaxel 120mg/m2~260mg/m2 tri-weekly with radiotherapy 1.8Gy/day (Total 39.6Gy)
Sponsors
Tokyo Women's Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Male and Femae who is More than 20 years Less than 80 years 2)Resectable Adenocarcinoma of esophago-gastric junction Stage2 or Stage3 3)Without metastasis of organs 4)Within 4weeks diagnosis using by GI or CT of Adenocarcinoma of esophago-gastric junction 5)Performance Status(ECOG)is 0or1 6)Without neoadjyuvant therapy 7)It is possible to perform chemo-radiotherapy before operation 8)The cases which meet criteria as follow1)White blood cell:more than 3,000/mm3 2)The number of neutrophil:more than1,500/mm3 3)The number of neutrophil:more than75,000/mm3 4)The amount of hemoglobin:more than9.0g/dl 5)AST or ALT is less than two point five times standard level in our institute 6)Creatinin is less than 1.5mg/dl 7)Neuropathy level is less than Grade 2 8)Total bililubin is less than 1.5mg/dL 9)Infomed consent is obtained
Exclusion criteria
Exclusion criteria: 1)Nobody performe nabpaclitaxcel before 2)Nobody use blood protacts within 2weeks3)Without drug hypersensitivity 4)Neuropathy level is more than Grade2 5)the patients who have another cancer in the time of entry. 6)With severe complication 7)With infection or chronic inflametory disease 8)Patient use the steroid 9)The patient is pregnancy 10)Male whose partner is pregnancy is possibility from now. 11)It is difficult to decide to take part in this trial with Mentaldisease 12)Docters decides patients are unsuitable for this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluation of maximum tolerated dose and recommended dose | — |
Secondary
| Measure | Time frame |
|---|---|
| Evaluation of Toxicity | — |
Countries
Japan
Contacts
Public ContactKosuke Narumiya
Tokyo Women's Medical University Department of Gastroenterological Surgery
Outcome results
None listed